Invesco Pharmaceuticals ETF (NYSEARCA:PJP) Trading Up 1% – Here’s What Happened

Invesco Pharmaceuticals ETF (NYSEARCA:PJP) traded up 1% on Monday . The company traded as high as $126.95 and last traded at $126.48. Approximately 17,473 shares were traded during trading, a decline of 51% from the average daily volume of 35,334 shares. The stock had previously closed at $125.26.

Invesco Pharmaceuticals ETF Stock Performance

The business has a 50-day moving average of $125.04 and a 200-day moving average of $114.21. The stock has a market capitalization of $549.51 million, a price-to-earnings ratio of 15.59 and a beta of 0.45.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Bank of America Corp DE raised its stake in shares of Invesco Pharmaceuticals ETF by 234.0% in the 1st quarter. Bank of America Corp DE now owns 74,458 shares of the company’s stock valued at $7,726,000 after acquiring an additional 52,165 shares during the period. Royal Bank of Canada boosted its position in shares of Invesco Pharmaceuticals ETF by 479.8% during the 1st quarter. Royal Bank of Canada now owns 62,377 shares of the company’s stock worth $6,472,000 after purchasing an additional 51,619 shares during the period. Northwestern Mutual Wealth Management Co. increased its holdings in Invesco Pharmaceuticals ETF by 829.5% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 25,941 shares of the company’s stock valued at $2,712,000 after purchasing an additional 23,150 shares during the last quarter. Cetera Investment Advisers increased its holdings in Invesco Pharmaceuticals ETF by 250.7% in the 1st quarter. Cetera Investment Advisers now owns 20,462 shares of the company’s stock valued at $2,123,000 after purchasing an additional 14,628 shares during the last quarter. Finally, Gilpin Wealth Management LLC acquired a new stake in Invesco Pharmaceuticals ETF in the 4th quarter valued at approximately $735,000.

Invesco Pharmaceuticals ETF Company Profile

PowerShares Dynamic Pharmaceuticals Portfolio (the Fund) is a non-diversified fund. The Fund seeks investment results that correspond generally to the price and yield of the Dynamic Pharmaceuticals Intellidex Index (the Index). The Index evaluates companies based on a variety of investment merit criteria, including fundamental growth, stock valuation, investment timeliness and risk factors. The Index consists of stocks of 30 United States pharmaceutical companies. These are companies that are principally engaged in the research, development, manufacture, sale or distribution of pharmaceuticals and drugs of all types.